IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients
Gao, Jing; Wang, Ting-ting; Yu, Jing-wei; Li, Yan-yan; Shen, Lin
关键词Kras Braf Mutation Cetuximab Colorectal Cancer
刊名CHINESE JOURNAL OF CANCER RESEARCH
2011-12-01
DOI10.1007/s11670-011-0271-4
23期:4页:271-275
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]GROWTH-FACTOR RECEPTOR ; PLUS IRINOTECAN ; PTEN EXPRESSION ; MUTATIONS ; TUMORS ; TUMORIGENESIS ; ONCOGENES ; BENEFIT
英文摘要

To analyze the relationship between KRAS, BRAF mutations and the response to Cetuximab in Chinese colorectal cancer patients.

A total of 273 Chinese colorectal cancer patients were evaluated for KRAS and BRAF mutations by Sanger sequencing. Among them, 59 patients with metastatic colorectal cancer (mCRC) were treated with Cetuximab in combination with chemotherapy from August 2005 to July 2009. Statistical analysis was conducted to assess the relationship between KRAS, BRAF mutations and the response or survival of 59 mCRC patients.

KRAS and BRAF mutation rates were 38.5% (105/273) and 5.1% (14/273), respectively, and KRAS/BRAF mutations were mutually exclusive. Among 59 patients treated with Cetuximab plus chemotherapy, KRAS and BRAF mutations were identified in 11 and 5 patients, respectively. The response rates and median progression-free survivals (PFS) in KRAS wild-type and mutant patients were 35.4% (17/48) vs. 9.1% (1/11) (P=0.054) and 153 days vs. 99 days (P=0.01), respectively. Also, the response rates and median PFS in BRAF wild-type and mutant patients were 37.2% (16/43) vs. 20% (1/5) (P=0.016) and 138 days vs. 90 days (P=0.036), respectively.

Besides KRAS, assessing BRAF mutation should also be required to select patients eligible for Cetuximab. Further prospective evaluation in large samples should be performed to confirm these preliminary findings.

语种英语
WOS记录号WOS:000298356300005
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56310
专题北京大学临床肿瘤学院
北京大学临床肿瘤学院_消化肿瘤内科
作者单位Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst,Dept Gastrointestinal On, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Gao, Jing,Wang, Ting-ting,Yu, Jing-wei,et al. Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients[J]. CHINESE JOURNAL OF CANCER RESEARCH,2011,23(4):271-275.
APA Gao, Jing,Wang, Ting-ting,Yu, Jing-wei,Li, Yan-yan,&Shen, Lin.(2011).Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients.CHINESE JOURNAL OF CANCER RESEARCH,23(4),271-275.
MLA Gao, Jing,et al."Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients".CHINESE JOURNAL OF CANCER RESEARCH 23.4(2011):271-275.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Gao, Jing]的文章
[Wang, Ting-ting]的文章
[Yu, Jing-wei]的文章
百度学术
百度学术中相似的文章
[Gao, Jing]的文章
[Wang, Ting-ting]的文章
[Yu, Jing-wei]的文章
必应学术
必应学术中相似的文章
[Gao, Jing]的文章
[Wang, Ting-ting]的文章
[Yu, Jing-wei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。